Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience

García, R Claramunt; Cid, Carmen Lucía Muñoz; Ruiz, A Sánchez; Pozo, Juan Francisco Marín

doi:10.1007/s00228-021-03235-5

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of VEGF‐A inhibition to downregulate pathological angiogenesis has been demonstrated in pre‐clinical studies of cancer and is well established. 50 , 51 , 52 , 53 , 54 , 55 Bevacizumab, which is currently used to downregulate angiogenesis in the treatment of metastatic colorectal cancer, 54 , 55 , 56 , 57 non‐squamous non‐small cell lung cancer 58 , 59 and hepatic cell carcinoma, 60 is used as a long‐term treatment and is often combined with chemotherapeutic agents. 61 , 62 , 63 To the best of our knowledge, we describe here the first studies to explore a potential therapeutic effect in inflammatory skin disease, demonstrating that VEGF‐A inhibition by bevacizumab exerts significant anti‐angiogenic activity in skin organ culture of psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of vascular endothelial growth factor‐A downregulates angiogenesis in psoriasis: A pilot study

Luengas‐Martinez

Ismail

Paus

et al. 2023

Skin Health and Disease

View full text Add to dashboard Cite

BackgroundVascular Endothelial Growth Factor (VEGF)‐A‐mediated angiogenesis participates in the pathogenesis of psoriasis, thus inviting the hypothesis that anti‐VEGF‐A therapy could be beneficial in psoriasis. While anti‐angiogenic agents are used in oncology and ophthalmology, these therapeutic strategies remain unexplored for the management of psoriasis.ObjectiveOur objective was to investigate ex vivo how VEGF‐A blockade impacts blood vessels, epidermis and immune cells in organ‐cultured plaque and non‐lesional skin from patients with psoriasis.MethodsSkin biopsies from patients with psoriasis (n = 6; plaque and non‐lesional skin) and healthy controls (n = 6) were incubated with anti‐VEGF‐A monoclonal antibody (bevacizumab, Avastin®) or a human IgG1 isotype control for 72‐h in serum‐free organ culture. CD31/LYVE‐1, Ki‐67, and mast cell tryptase expression were assessed by quantitative immunohistomorphometry. VEGF‐A levels in plasma, PBMCs and skin culture supernatants were measured.ResultsInhibition of VEGF‐A blocked all free VEGF‐A ex vivo, reduced blood vessel area and the number of blood vessel endothelial cells in plaques of psoriasis (*p < 0.05). The treatment effect correlated significantly with levels of VEGF‐A in organ culture supernatants (r = 0.94; *p < 0.05) from plaque skin and with plasma levels of VEGF‐A from patients with psoriasis (r = 0.943; *p = 0.017).ConclusionsThese ex vivo data are the first studies to objectively investigate the potential of VEGF‐A inhibition as a novel adjuvant treatment strategy for psoriasis. Taken together, our data encourage further investigation by clinical trial to explore whether downregulating pathological angiogenesis has clinical utility, especially in patients with severe psoriasis or those with elevated levels of VEGF‐A in plasma and/or skin.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of vascular endothelial growth factor‐A downregulates angiogenesis in psoriasis: A pilot study

Luengas‐Martinez

Ismail

Paus

et al. 2023

Skin Health and Disease

View full text Add to dashboard Cite

show abstract

Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis

Chen,

Huang,

et al. 2023

World J Surg Onc

View full text Add to dashboard Cite

Background Systemic therapy is the standard treatment for unresectable colorectal cancer with liver metastasis (CRCLM). Transarterial chemoembolization with drug-eluting beads (DEB-TACE) is considered an effective treatment option for CRCLM. Few studies have investigated the combination of DEB-TACE, chemotherapy, and targeted therapy for CRCLM. In the present study, we evaluated the disease control rate (DCR), adverse events, and survival among patients with CRCLM who underwent the combination of DEB-TACE and chemotherapy/targeted therapy. Materials We retrospectively reviewed 35 patients with CRCLM who were treated between January 2015 and January 2021. Standard systemic chemotherapy, targeted therapy, and 66 DEB-TACE procedures were administered. Data were collected on each DEB-TACE procedure, including chemotherapy agents, tumor burden of liver metastasis, number of DEB-TACE courses, and adverse events. Patients who received DEB-TACE after failure of first-line systemic therapy were categorized into the first-line failure group. Patients who received DEB-TACE after the failure of second-line, third-line, or fourth-line therapy were categorized into the other group. Subgroup analysis was performed to compare overall survival (OS) and progression-free survival (PFS) between the two groups. Results In total, 35 patients with CRCLM (34 patients with adenocarcinoma and 1 patient with neuroendocrine carcinoma) were enrolled. In total, 13 patients (37.1%) had extrahepatic metastases at initial diagnosis. In this study, 66 DEB-TACE procedures were performed. The DCR was 54.3%. The median OS period was 47.4 months, and the estimated 3-year OS rate was 59.5%. The median PFS period was 6.3 months, and the estimated 1-year PFS rate was 20.6%. The PFS period was longer in the first-line failure group than in the other group (7.2 vs. 6.3 months). No significant difference was observed in OS between the two groups. Four episodes (6.1%) of grade 3 intra-abdominal infection were observed. Conclusion The combination of chemotherapy, targeted therapy, and DEB-TACE can lead to a favorable DCR and survival outcomes in patients with CRCLM. Early intervention with DEB-TACE (i.e., after the failure of first-line therapy) has the potential to extend the PFS period in patients with CRCLM. Severe adverse events were rare and manageable. Further prospective, randomized controlled studies are warranted to obtain more conclusive findings.

show abstract

Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience

Cited by 2 publications

References 4 publications

Inhibition of vascular endothelial growth factor‐A downregulates angiogenesis in psoriasis: A pilot study

Inhibition of vascular endothelial growth factor‐A downregulates angiogenesis in psoriasis: A pilot study

Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis

Contact Info

Product

Resources

About